| Metric | Value ($ M) | vs Q1 FY26 |
|---|---|---|
| Revenue | 1.71 | 0.0% |
| Total Income | 1.71 | 0.0% |
| Expenditure | 10.54 | 4.9% |
| PBT | — | |
| Net Profit | -7.39 | 5.1% |
| OPM | — | |
| NPM | — | |
| EPS | -0.04 | 0.0% |
Rani Therapeutics Reports Q2 2026 Financial Results and Provides Corporate Update
14 Aug 2026 · 14 Aug, 1:50 am
Summary
Rani Therapeutics reported its financial results for the second quarter ended June 30, 2026, alongside a corporate update. The company generated $1.7 million in contract revenue for the quarter, up from zero in the prior year's period, attributed to a Chugai agreement. Total operating expenses remained stable year-over-year at $10.5 million, resulting in a reduced net loss of $8.4 million for the quarter compared to $11.2 million in Q2 2025. The company also highlighted positive initial Phase 1a data for its RT-114 program, demonstrating significant oral bioavailability, and confirmed its cash position is expected to fund operations through 2027.
Key Highlights
- 1
Rani Therapeutics reported financial results for the second quarter ended June 30, 2026.
- 2
Contract revenue for the three months ended June 30, 2026 was $1.7 million, an increase from no contract revenue in the same period of 2025, primarily due to a collaboration and license agreement with Chugai.
- 3
Research and development expenses for Q2 2026 were $5.0 million, a decrease from $5.5 million in Q2 2025.
- 4
General and administrative expenses for Q2 2026 were $5.5 million, an increase from $5.0 million in Q2 2025.
- 5
Net loss for the three months ended June 30, 2026 was $8.4 million, an improvement from a net loss of $11.2 million for the same period in 2025.
- 6
Cash, cash equivalents and marketable securities totaled $53.4 million as of June 30, 2026, and the company expects this to be sufficient to fund operations at least through 2027.
- 7
The company announced positive initial Phase 1a data for RT-114, showing oral bioavailability greater than 150% relative to matched subcutaneous dosing.
Management Comments
Talat Imran
We made significant progress in the second quarter, as we continue to expand the RaniPill® oral delivery platform. We reported positive initial Phase 1a data for RT-114 showing oral bioavailability that exceeded matched subcutaneous dosing. These data are consistent with the bioavailability that we have seen in previous preclinical and clinical studies with the RaniPill. We have continued to advance the program in the clinic, with additional data from the dose expansion cohort expected by the end of 2026. We also continued to expand our obesity franchise through a new collaboration with PegBio leveraging the RaniPill platform to explore the oral delivery of novel obesity and metabolic disease molecules across multiple mechanisms of action. I am also pleased to have welcomed Nicholas Maestas as our Chief Financial Officer and Michelle Gilson to our Board of Directors. Together, these clinical and corporate milestones, along with the completion of a $20 million registered direct offering, position Rani to make further progress in the development of the RaniPill as an oral delivery for biologic candidates.
Informational and educational content only. Not investment advice.